Transaction in Own Shares


Novo Nordisk A/S - Share repurchase programme

On 7 August 2009 Novo Nordisk initiated its share repurchase
programme in accordance with the provisions of the European
Commission's regulation no 2273/2003 of 22 December 2003, also
referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an
amount up to DKK 2.4 billion in the period from 10 August 2009 to 18
December 2009.

Since the announcement as of 7 September 2009, the following
transactions have been made under the programme:


                 Number of Average             Transaction
                  shares   purchase   value,                   DKK
                            price
Accumulated,
last             1,521,000                                479,133,986
announcement
7 September 2009    55,000 316.5500                        17,410,250
8 September 2009    66,000 319.0900                        21,059,940
9 September 2009    75,000 318.5030                        23,887,725
10 September        75,000 322.2300                        24,167,250
2009
11 September        75,000 326.5450                        24,490,875
2009
Accumulated
under the        1,867,000                                590,150,026
programme


With the transactions stated above, Novo Nordisk owns a total of
26,703,808 treasury shares, corresponding to 4.3% of the share
capital. The total amount of shares in the company is 620,000,000
including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 27,900
employees in 81 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.

Further information:


Media:                 Investors:

Outside North America: Outside North America:
Mette Kruse Danielsen  Mads Veggerby Lausten
Tel: (+45) 4442 3883   Tel: (+45) 4443 7919
mkd@novonordisk.com    mlau@novonordisk.com

                       Kasper Roseeuw Poulsen
                       Tel: 4442 4471
                       krop@novonordisk.com

In North America:      In North America:
Sean Clements          Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com   hrmm@novonordisk.com


Company Announcement No 54 / 2009

Attachments

Company Announcement No 54 2009.pdf
GlobeNewswire